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Abstract We have characterised a novel aldo-keto reductase
(AKR7A5) from mouse liver that is 78% identical to rat a£a-
toxin dialdehyde reductase AKR7A1 and 89% identical to hu-
man succinic semialdehyde (SSA) reductase AKR7A2. AKR7A5
can reduce 2-carboxybenzaldehyde (2-CBA) and SSA as well as
a range of aldehyde and diketone substrates. Western blots
show that it is expressed in liver, kidney, testis and brain, and
at lower levels in skeletal muscle, spleen heart and lung. The
protein is not inducible in the liver by dietary ethoxyquin. Im-
munodepletion of AKR7A5 from liver extracts shows that it is
one of the major liver 2-CBA reductases but that it is not the
main SSA reductase in this tissue. 1 2002 Published by Else-
vier Science B.V. on behalf of the Federation of European Bio-
chemical Societies.
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1. Introduction
Aldehydes and ketones form the reactive group in many
endogenous and exogenous compounds, many of which are
toxic, mutagenic or carcinogenic [1]. The ability of mamma-
lian cells to metabolise these compounds depends on the pres-
ence of enzymes, including members of the aldo-keto reduc-
tase (AKR) family [2], aldehyde dehydrogenases [3], alcohol
dehydrogenases [4], carbonyl reductase [5], quinone reductase
[6] and glutathione S-transferases (GSTs) [7].
Studies on the roles of AKR in carbonyl metabolism have
assumed greater prominence in recent years, and this family
currently comprises 12 subfamilies (AKR1^AKR12) [8,9].
Mouse liver AKRs represent a group of enzymes that contrib-
ute to the metabolism of exogenous and endogenous com-
pounds. Enzymes present in adult mouse liver that have
been cloned and characterised to date include AKR1C6
(17-L-hydroxysteroid dehydrogenase) [10], AKR1C12 and
AKR1C13 [11], and AKR1E1 [12]. However, no members
of the major aldehyde reductase AKR1A subfamily have
been identi¢ed in mouse liver to date. The distantly related
AKR7 family includes the rat liver a£atoxin B1 aldehyde re-
ductase or AFAR (AKR7A1), a second rat enzyme AKR7A4
[13,14] and two human homologues AKR7A2 [15] and
AKR7A3 [16].
AKR7A1 was originally discovered as an inducible a£atox-
in B1 dialdehyde reductase present in the livers of rats fed on
diets containing the synthetic antioxidant ethoxyquin [17,18].
Subsequent studies revealed that AKR7A1 is also induced by
a wide range of xenobiotics including butylated hydroxyani-
sole, coumarin, oltipraz and benzyl isothiocyanate [19]. It is
thought the gene is transcriptionally activated via an antioxi-
dant responsive element [20]. Following the characterisation
of this inducible rat AKR, another related reductase has been
found in rat (AKR7A4) [13] and two related human reduc-
tases (AKR7A2 and AKR7A3) [15,16] have also been iso-
lated. Enzyme studies of these rat and human AKR7 enzymes
have shown that they are capable of reducing a£atoxin
B1 aldehyde [15,16,21]. In addition, rat AKR7A1, human
AKR7A2 and human AKR7A3 have all been shown to have
substantial activity towards succinic semialdehyde (SSA), sug-
gesting that this compound, which is derived from Q-amino-
butyrate (GABA), may represent an important physiological
substrate for the AKR7A enzyme family [13,15,16,22]. Both
rat AKR7A4 and human AKR7A2 proteins have been iden-
ti¢ed in brain, suggesting a potential role in the biosynthesis
of Q-hydroxybutyrate (GHB), an important neurotransmitter,
from SSA [23]. In addition to exhibiting SSA reductase activ-
ity, AKR7A family members are also able to metabolise
2-carboxybenzaldehyde (2-CBA), a compound that is struc-
turally similar to SSA. Very few other AKRs can reduce
2-CBA, making this a relatively speci¢c substrate for
AKR7A family members. Crystallisation of AKR7A1 has al-
lowed the structure of this dimeric AKR to be determined,
and has provided a structural basis for the enzyme’s ability
to reduce 4-carbon acid aldehydes such as 2-CBA and SSA
[24].
A precise physiological function based on substrate speci-
¢city or tissue distribution alone has been di⁄cult to deter-
mine for any of the currently known AKR7A enzymes. At
present it is not clear whether the rat AKR7A1 is the func-
tional homologue of either human AKR7A2 or AKR7A3 and
there is no available evidence to suggest that either of the
human enzymes is inducible. Because of the potential useful-
ness of mouse as a model for investigating in vivo carbonyl
metabolism and detoxication, the cloning, expression, and
characterisation of a hitherto unrecognised AKR7A enzyme
in the mouse is described, which it is hoped will lead to future
in vivo functional analysis of the AKR7A gene family.
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2. Materials and methods
2.1. Cloning of mouse AKR7A5 cDNA
Comparison between rat AKR7A1 nucleotide sequences and other
cDNAs was carried out by BLAST searching [25] against the Gen-
Bank database. A partial mouse AKR7A5 complementary DNA was
initially ampli¢ed by RT-PCR using total mouse liver RNA as a
source and oligos designed to the expressed sequence tag (EST) se-
quences AA111743 and W50781 (MA3 ^ 5P-CCG.GAATTC.GCGT-
CGCATGGATGCGAGTGCTGCTAGCG-3P and MA2 ^ 5P-CGG.
GGTACC.GGACACTCGTGGGCGACC-3P). This truncated cDNA
was cloned into pT7Blue3 to give pAH10 and was used to probe
Northern blots. To determine the full-length cDNA sequence,
SMART (switching mechanism at 5P end of RNA transcript) RACE
(rapid ampli¢cation of cDNA ends) PCR was performed. Two gene
speci¢c primers for the 3P and 5P RACE (GSP1 ^ 5P-CGTCCGGTC-
CCAGTTAGAGACGTCTCTG-3P ; GSP2 ^ 5P-CCAAAGAAGCG-
GCCCACGGGTTGTTTCC-3P) were used in conjunction with prim-
ers speci¢c for oligonucleotides that had been incorporated into the
5P and 3P ends of cDNA derived from mouse liver mRNA. The full-
length cDNA was then ampli¢ed from reverse-transcribed mouse
liver RNA, using two oligonucleotides, one of which (mAFAR-
FOR 5P-CGCTCCGGGACTTCGGTCGGGC-3P) was designed to
a third EST (accession no. AI893701) and the other (mAFARRev
5P-TGCTTTATTCAGACAGGA-3P) was designed to the 3P end
from the sequence derived from the SMART RACE PCR. The se-
quence of the amplicon was veri¢ed and it was then used as template
for a second round of PCR with primers: mAFAR1 5P-CCG-
GAATTCCAT.ATGTCCCGGCCTCCGCCACCCCGC-3P (forward)
and mAFAR2 5P-CGGCTCGAG.CTATCTGAAGTAGGTTGGGA-
CA-3P (reverse) which included 5P EcoRI and NdeI sites and a 3P XhoI
site. This full-length mouse AKR7 cDNA was blunt cloned into the
multiple cloning site of pT7Blue3 (Novagen) between the EcoRI sites
resulting in pAH11. The DNA insert in pAH11 was sequenced to
verify ¢delity of ampli¢cation using dye terminators and Amplitaq
FS DNA polymerase and separated on an ABI (Applied Biosystems)
373A automated sequencer. Multiple sequence alignments of AKR7A
family members were carried out using Clustal-X [26].
2.2. Bacterial expression and isolation of recombinant AKR7A enzyme
The coding region for mouse AKR7A5 was excised from pAH11 by
digestion with NdeI and XhoI, and ligated into the NdeI and XhoI
sites of pET15b expression vector. The resulting expression construct
pAH12 was used to transform Escherichia coli BL21 pLysS. Expres-
sion of recombinant His-tagged AKR7A5 protein was induced for
1.5 h at 37‡C by the addition of 0.5 mM isopropyl L-D-thiogalactoside
to mid-exponential phase transformed BL21 pLysS cells. Cells were
harvested by centrifugation, frozen at 370‡C, and lysed using a son-
icator in bu¡er A (20 mM sodium phosphate, 500 mM NaCl pH 7.4).
Lysates were ¢ltered through a 0.45 Wm Whatman polysulphone disc,
and loaded onto a 5 ml HiTrap Chelating a⁄nity column (Pharmacia
Biosystems Ltd., Milton Keynes, Herts, UK), pre-equilibrated with
bu¡er A. After washing the column, recombinant polyhistidine-tagged
protein was recovered by elution with 200 mM imidazole in bu¡er A.
The eluted recombinant protein was then passed through a G25 gel
¢ltration system column, equilibrated with 20 mM sodium phosphate
bu¡er (pH 6.6) to remove the imidazole and salt. 10% (v/v) glycerol
was added and puri¢ed enzyme to be stored at 370‡C. Removal of
the His-tag was achieved using human thrombin (Sigma, Poole, UK).
Molecular weight estimation was performed using a DYNA-PRO 801
dynamic light scattering/molecular sizing instrument (Protein Solu-
tions, Buckingham, UK).
2.3. Antibodies to AKR7A5
Puri¢ed mouse AKR7A5 (approximately 100 Wg in 1 ml 10 mM
sodium phosphate bu¡er; pH 7) was emulsi¢ed with an equal volume
of Freund’s complete adjuvant and injected subcutaneously at four
separate sites on the back of two female New Zealand White rabbits.
After 14 days each rabbit was re-inoculated with 100 Wg of the orig-
inal immunogen in incomplete Freund’s adjuvant and this was fol-
lowed by a ¢nal inoculation 10 days later, this time with 100 Wg of
immunogen in 0.9% saline. After a further 10 days the animals were
killed and bled. The serum obtained was stored at 320‡C, in the
presence of 0.1% sodium azide until required.
2.4. Protein and enzyme assays
Protein concentrations were measured using the method of Brad-
ford [27] and standardised using bovine serum albumin, using a kit
from Bio-Rad Laboratories Ltd. (Hemel Hempstead, UK). Aldehydes
and ketone substrates were obtained from Sigma Chemical Co.
(Poole, Dorset, UK) or from Aldrich Chemical Co. (Gillingham, Dor-
set, UK). A£atoxin B1 dialdehyde was prepared using previously de-
scribed methods, which allow the formation of the dialdehyde from
the dihydrodiol [28]. Aldehyde- and ketone-reducing activity was
routinely measured with a Beckman DU650 UV single-beam record-
ing spectrophotometer by following the initial rate of oxidation of
NADPH at 340 nm (n=6270 M31 cm31) as described previously
[22]. Apparent Km values for mouse AKR7A5 were determined by
measuring the initial reaction rate over a range of substrate concen-
trations and were calculated using Ultra¢t curve-¢tting software (Bio-
soft, Cambridge, UK) using the Marquardt algorithm.
2.5. Protein gels and Western blots
SDS^PAGE was performed in 12% polyacrylamide resolving gels
with the bu¡er system described by Laemmli [29]. For Western blot-
ting, electrophoretic transfer of polypeptides from SDS^PAGE gels to
nitrocellulose membranes was carried out using a Bio-Rad minigel
apparatus. Protein binding sites on membranes were blocked over-
night in TBST (20 mM Tris^HCl/150 mM NaCl/0.01% (v/v) Tween)
which contained 10% (w/v) skimmed milk. The blots were then incu-
bated for 1 h at room temperature with antisera against AKR7A5 or
NAD(P)H:quinone oxidoreductase (NQO1) (at 1:2000 dilution in
TBST). After washing, horseradish peroxidase-conjugated secondary
antibody (goat anti-rabbit IgG, at 1:3000 dilution) in TBST was
added. The antibody complexes were detected using enhanced chemi-
luminescence (ECL; Amersham).
2.6. Animals and preparation of tissue extracts
Eight week old male CD-1 mice were fed a basic diet of powdered
food with arachis oil, or the basic diet/arachis oil plus 0.5% (w/w)
ethoxyquin, butylated hydroxyanisole, coumarin or benzyl isothiocya-
nate for 7 days immediately before sacri¢ce. Upon removal, the or-
gans from the CD-1 mice were snap-frozen and stored at 370‡C until
use. To prepare the cell extracts approximately 100 mg of each tissue
was taken and homogenised in 20 mM NaPO4 bu¡er (pH 7.0). After
centrifugation to remove cell debris, supernatant fractions were stored
at 380‡C.
AKR7A5 was immunodepleted from total liver extracts as follows:
a 100 Wl aliquot of preswollen protein A-Sepharose beads (approxi-
mately 50% slurry) was added to 200 Wl of antisera (either against
AKR7A5 or LDH). After incubation at 4‡C for 1 h, portions of
extracts containing equivalent amounts of AKR7A5 (as estimated
from quantitative Western blots) diluted into 200 Wl of ice-cold
10 mM sodium phosphate bu¡er (pH 8.0) were added to each of
the protein^antibody mixtures; after incubation at 4‡C for 2 h, the
beads were removed by centrifugation. Complete removal of
AKR7A5 from the extracts was veri¢ed by Western blot analysis of
the supernatants (data not shown). The resulting AKR7A5- and
LDH-depleted supernatants were then assayed for carbonyl-reducing
activity.
3. Results and discussion
3.1. Identi¢cation and cloning of mouse AKR7A5
The rat AKR7A1 sequence was used to carry out a BLAST
search against the GenBank database. This identi¢ed several
mouse ESTs whose predicted gene products showed extensive
similarity to AKR7A1 at the amino acid level. Two of these
sequences (AA111743 and AI893701) were derived from adult
kidney cDNA whereas the third was embryonic in origin.
These ESTs were identical in their overlapping regions, sug-
gesting that they were derived from the same gene (Fig. 1).
SMART RACE PCR was used in an attempt to determine
whether the sequence represented the full-length mouse
AKR7A-related sequence. Sequencing of these amplicons re-
vealed additional sequence at the 3P end, including the polyA
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tail. However, no additional sequence could be determined at
the 5P end beyond that which was present in EST AI893701.
To con¢rm that this sequence represents a bone ¢de cDNA
that is expressed in mouse liver, RT-PCR was performed from
mouse liver total RNA using primers to the 5P and 3P ends of
the proposed sequence. A PCR product of 1.01 kb was iso-
lated, cloned and the full-length sequence was con¢rmed by
DNA sequencing. The consensus sequence resulted in an open
reading frame of 1017 bp, which would translate to a poly-
peptide of 338 residues with an estimated molecular mass of
37 662 Da. Comparison of this putative mouse AKR7A and
other already identi¢ed AKR7A enzymes (Fig. 2) showed
these proteins are highly related. At the amino acid level the
putative mouse AKR7A is 78% identical to the ethoxyquin-
inducible a£atoxin dialdehyde reductase (AFAR; AKR7A1)
from rat liver and 88% identical to both human AKR7A2 and
AKR7A3. From this sequence similarity alone it might be
expected to perform a similar role to one or more of these
enzymes. In common with its close relatives, it shares less than
20% identity with other mouse AKRs in the major AKR1
family, and also shows some similarity in structure and se-
quence to the voltage-gated Shaker-related Kþ channel L-sub-
unit AKR6 family. The four amino acids forming the catalytic
tetrad shown to be involved in catalysis in other AKRs [30]
are conserved in mouse AKR7A (Tyr-56, His-130, Lys-84 and
Asp-51), suggesting that the mouse sequence is likely to en-
code an active enzyme.
3.2. Catalytic properties of mouse AKR7A5
To determine whether the mouse AKR7A-related protein
was catalytically active, the coding region was cloned into a
bacterial expression vector, and the protein puri¢ed as de-
scribed previously for rat AKR7A1 [18]. Removal of the
N-terminal His-tag using thrombin resulted in a protein which
co-migrated with an AKR7-related protein present in mouse
liver extracts (Fig. 3A), indicating that it represents the full-
length protein that is expressed in liver. Dynamic light scatter-
ing analysis showed the puri¢ed protein to be monodispersed,
with a hydrodynamic radius of 3.8 nm, giving it an estimated
molecular weight of 77 kDa. This means that the puri¢ed
recombinant protein is a dimer, a feature which it shares
with rat AKR7A1 and AKR7A4 [13,24].
Enzyme assays were performed which showed that the pu-
ri¢ed recombinant mouse protein was able to reduce the mod-
Fig. 1. Alignment of mouse EST showing similarity to rat AKR7A1
cDNA. Three ESTs were identi¢ed by using the AKR7A1 cDNA
sequence to perform BLAST search of the GenBank database. Ad-
ditional 3P sequence was derived from 3P RACE of mouse liver
mRNA. The full-length sequence has been deposited in the EMBL
database.
Fig. 2. Multiple sequence alignment of full-length mouse AKR7A5
with rat and human AKR7A sequences. Clustal-X multiple sequence
alignment between the amino acid sequences of AKR7A5 and other
AKR7A. *, identical amino acids; : and ., conserved amino acids;
+, amino acids corresponding to the catalytic tetrad.
Fig. 3. Detection of AKR7A5 in mouse tissues. Detection of re-
combinant AKR7A5 and an AKR7A5-related band in mouse tissues
was carried out by separating puri¢ed protein and tissue extracts by
SDS^PAGE and subjecting to Western blotting. The membranes
were probed with antisera raised to AKR7A5 and detected using
ECL. A: 1, Recombinant AKR7A5; 2, recombinant AKR7A5 after
cleavage of the His-tag with thrombin; 3, 10 Wg mouse liver extract.
B: 10 Wg extract of the mouse tissues indicated.
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el substrate 4-nitrobenzaldehyde (4-NBA). It was therefore
given the name AKR7A5 as it represents the ¢fth active mem-
ber of the subfamily to be characterised. Like the rat and
human AKR7A enzymes, the mouse enzyme can use both
NADH and NADPH as cofactor (Table 1). Using 4-NBA
as a substrate, and NADPH as a cofactor, the optimum pH
for the mouse AKR7A5 was determined and found to be pH
6.6, but the enzyme can function over a broad range (pH 5.0^
9.0). AKR7A5 also demonstrates a broad range of substrate
speci¢cities for aldehydes and diketones, including drugs,
toxic aldehydes, and metabolites.
The apparent Michaelis constants of the recombinant
mouse AKR7A5 for some relevant substrates were determined
(Table 1). Mouse AKR7A5 can reduce the dialdehyde form of
AFB1-dihydrodiol (pH 8.5), although it has a lower a⁄nity
(Km 90 WM) compared with that determined previously for the
rat and human enzymes (9 WM) [16,21]. This is particularly
salient because it had been thought that an a£atoxin-metab-
olising aldehyde reductase would not be important for detox-
ication of this compound in mouse because of the high con-
stitutive presence of a speci¢c alpha class GST in this species.
This GST is able to conjugate the a£atoxin 8,9-epoxide and
was thought to be responsible for conferring the high level of
resistance to a£atoxin B1 seen in mouse [31]. A similar GST is
inducible in rat [32]. In humans, the AKR7A enzymes are
considered to assume greater importance [21]. The catalytic
e⁄ciency that we observe suggests that AKR7A5 may also
make a contribution to a£atoxin resistance in the mouse.
AKR7A5 is also capable of reducing trans, trans-muconal-
dehyde which is a toxic metabolite of benzene and has been
linked to the occurrence of leukaemia. The endogenous mono-
amine oxidase inhibitor isatin has been shown previously to
be a good substrate for human AKR7A2 [15], and likewise, it
is also a good substrate for mouse AKR7A5 with a Km of 109
WM. However, mouse AKR7A5 has very weak a⁄nity for
some dicarbonyls such as diacetyl (Km 58 mM), which marks
it as clearly di¡erent from rat AKR7A1. The a⁄nity of the
enzyme for NADH is signi¢cantly lower than that observed
for NADPH (Table 1) when using 4-NBA as substrate.
The kinetic constants of the mouse, rat and human AKR7A
enzymes were compared for some model AKR substrates:
SSA, 9,10-phenanthrenequinone (9,10-PQ), 4-NBA and also
2-CBA, which has been identi¢ed as a relatively speci¢c sub-
strate for AKR7A enzymes (Table 2). Mouse AKR7A5 had a
similar a⁄nity for 4-NBA (Km = 870 WM) as rat AKR7A1
(Km = 520 WM), whereas human AKR7A2 had signi¢cantly
lower a⁄nity (Km = 6630 WM). All of the AKR7A enzymes
tested reduced the bulky hydrophobic dicarbonyl compound
9,10-PQ, but the mouse and human enzymes have higher af-
¢nity and catalytic activity. SSA, which has been shown pre-
viously to be reduced by human AKR7A2 [15], is also reduced
e⁄ciently by mouse AKR7A5, whereas rat AKR7A1 has a
much lower a⁄nity and turn over rate than the mouse or
human enzyme.
3.3. Tissue distribution of mouse AKR7A5
Antibodies raised against mouse AKR7A5 were used to
probe Western blots of various mouse tissue protein extracts
(Fig. 3B). Mouse AKR7A5 antibodies reacted with a protein
band in most tissues tested; however, levels are highest in
liver, kidney, testis and brain, and lower levels were found
in the heart, spleen, and skeletal muscle. This pattern of ex-
pression di¡ers from rat AKR7A1, as the rat protein is only
detectable at low levels in the livers of control rats and is
present additionally only in testis, kidney and small intestine
[18]. The tissue distribution of AKR7A5 is more similar to
that seen for the human AKR7A2 protein which is expressed
in most tissues and is detected at high levels in liver, kidney,
Table 1
Apparent kinetic constants for mouse AKR7A5 for aldehyde and diketone substrates
Substrate Mouse AKR7A5
Km (WM) Kcat (min31) Kcat=Km (min31 M31)
4-NBA 870W 500 46W 6 5.34U104
9,10-PQ 8.0W 4.0 62W 6 7.69U106
2-CBA 16W 3 78W 17 4.86U106
SSA 20W 10 80W 12 4.02U106
AFB1-dihydrodiol (pH 8.5) 90W 30 34W 7 3.77U105
Isatin 109W 26 54W 3 4.99U105
2-NBA 460W 140 75W 11 1.63U105
Methyl glyoxal 3 980W 940 47W 3 1.18U104
Camphorquinone 4 990W 490 66W 3 1.32U104
Trans, trans-muconaldehyde 7 190W 5 990 94W 41 1.31U104
Diacetyl 58 420W 16 410 114W 1 1.96U103
NADPH 1.62W 0.01 26W 3 1.58U107
NADH 1470W 23 115W 101 7.86U104
The activity of AKR7A5 towards carbonyl-containing compounds was determined at 25‡C as described in Section 2 using NADPH as cofactor.
Apparent Km and Kcat values were estimated from the initial velocities measured over a range of substrate concentrations using the Ultra¢t
curve-¢tting programme. The values shown represent meanWS.E.M. The Km and Kcat for NADPH and NADH were estimated using 4-NBA
as substrate.
Table 2
Comparison of catalytic e⁄ciency of recombinant mouse AKR7A5,
rat AKR7A1 and human AKR7A2
Kcat/Km (min31 M31)
Mouse AKR7A5 Rat AKR7A1 Human AKR7A2
4-NBA 5.34U104 9.55U104 1.1U104
9,10-PQ 7.69U106 4.13U106 1.48U107
2-CBA 4.86U106 1.41U107 1.14U107
SSA 4.00U106 1.06U106 3.02U106
2-NBA 1.62U105 1.4U105 6.23U104
The activities of AKR7A5, AKR7A1 and AKR7A2 towards car-
bonyl-containing compounds were determined at 25‡C as described
in Section 2 using NADPH as cofactor. Apparent Km and Kcat val-
ues were estimated from the initial velocities measured over a range
of substrate concentrations using the Ultra¢t curve-¢tting pro-
gramme.
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testis and, importantly, brain [33]. The narrow tissue distribu-
tion of the rat enzyme suggested that it has a specialised tissue
speci¢c role, possibly in detoxication. By contrast, the more
widespread rat AKR7A4 and human AKR7A2 tissue distri-
bution suggests that these enzymes may perform a ‘house-
keeping’ role, possibly in metabolism [13,15]. Overall, the
mouse enzyme distribution seems to ¢t more closely with
the latter two enzymes, suggesting that it too performs a
house-keeping role.
3.4. Induction of mouse liver enzymes by chemoprotectors
An unusual feature of the rat AKR7A1 is that its expres-
sion in liver is inducible by a variety of chemopreventive com-
pounds, including synthetic antioxidants such as ethoxyquin,
butylated hydroxyanisole and oltipraz [34]. It is therefore con-
sidered to be a key detoxication enzyme that is part of an
adaptive stress response to chemical and oxidative stress
[20]. In contrast, rat AKR7A4 is found to be constitutively
expressed in the liver [13]. To determine whether AKR7A5
was inducible, mice were fed on diets containing ethoxyquin,
butylated hydroxyanisole, coumarin, and benzyl isothiocya-
nate for 7 days and the livers examined for increased expres-
sion of AKR7A5 and NQO1, an enzyme previously shown to
be inducible by these compounds. Fig. 4 shows that although
the treatments lead to the induction of NQO1, there is no
increase in the levels of AKR7A5. The lack of inducibility
of AKR7A5 suggests that AKR7A5 is assuming a role similar
to the constitutive rat AKR7A4. It is possible that the induc-
ibility of AKR7A1 is a feature unique to the rat. Neither of
the human enzymes AKR7A2 and AKR7A3 has been shown
to be inducible in the liver, though there does appear to be
some interindividual variation in expression levels and activ-
ities [21,33].
3.5. Contribution of mouse AKR7A5 to liver carbonyl-reducing
activity
A low Km for SSA suggested that the mouse AKR7A5
could function as a SSA reductase in vivo, as has been pro-
posed for human AKR7A2 [15]. To assess the role of mouse
AKR7A5 in the metabolism of SSA in liver, we depleted liver
extracts using antibodies raised to AKR7A5 (Fig. 5). This
showed that SSA reductase activity in mouse liver does not
decrease when mouse AKR7A5 is removed, which indicates
that it is not the primary SSA reductase enzyme in mouse
liver. In many tissues, SSA is produced from GABA by
GABA-transaminase and is metabolised by SSA dehydroge-
nase to succinic acid. However, SSA can also be reduced by
SSA reductase in some tissues to GHB, particularly where
SSA dehydrogenase is not ubiquitously expressed. GABA-
transaminase is widely distributed in non-neural tissues, in-
cluding liver, kidney and testis whereas SSA dehydrogenase
is absent from some of those tissues such as the testis. A role
for AKR7A2 in the reduction of SSA has been supported by
the puri¢cation of AKR7A2 from human brain as a major
SSA reductase [23]. Similarly, AKR7A-related proteins are
expressed in rat brain [13,35]. However, it has been demon-
strated that AKR7A2 does not constitute the major SSA re-
ductase in human liver [15], as the major peak of SSA reduc-
tase activity does not copurify with AKR7A2. A similar
observation was seen in rat liver where neither of the two
rat enzymes AKR7A1 or AKR7A4 was present in the major
SSA reductase peak [13]. Our results suggest that AKR7A5 is
not the major SSA reductase in liver, which is concordant
with it paralleling the function of human AKR7A2. Presum-
ably another AKR such as an aldehyde reductase of the
AKR1 family contributes the majority of SSA reductase ac-
tivity in the liver. Further work is required to establish
whether AKR7A5 is a major SSA reductase in mouse brain,
particularly if other AKRs are not present in this tissue.
Immunodepletion experiments did, however, reveal that
there is a signi¢cant decrease (40%) in hepatic 2-CBA reduc-
tase activity following removal of AKR7A5 from the extracts.
2-CBA is a carbonyl compound that is of interest to the
pharmaceutical industry because it is used to mask drugs
and enhance their delivery to target sites [36,37]. It has been
previously reported that AKR7A2 is the principal 2-CBA re-
ductase in human liver [15], and our data suggest that this role
may also be shared by AKR7A5 in mouse liver. Immunode-
pleted extracts also showed that AKR7A5 is responsible for
approximately 15% of the total hepatic 4-NBA reductase ac-
tivity (Fig. 5), but did not show any decrease in 9,10-PQ
reductase activity, suggesting that it is not the major liver
enzyme responsible for the reduction of this compound
(Fig. 5).
Fig. 4. Induction of mouse liver enzymes by chemoprotectors. Por-
tions (10 Wg) of hepatic extract from control male mice and from
male mice that had been fed ethoxyquin, tert-butyl hydroquinone,
coumarin, indole-3-carbinol or benzyl isothiocyanate were separated
by electrophoresis on a single SDS^PAGE gel. After blotting, the
nitrocellulose membrane was probed with antisera raised to
AKR7A5 or NQO1. Cross reacting polypeptides were visualised by
ECL. 1, Control diet; 2, coumarin; 3, ethoxyquin; 4, butylated hy-
droxyanisole; 5, benzyl isothiocyanate.
Fig. 5. Carbonyl-reducing activities in hepatic cytosols immunode-
pleted for AKR7A5. Extracts from the livers of three mice that had
been fed either control diet or control diet plus ethoxyquin were in-
cubated with antisera raised against AKR7A5 (open bar) or LDH
(speckled bar) (as a control) and protein A-Sepharose beads. After
removal of the beads by centrifugation, the remaining activities in
the immunodepleted samples were assayed for the substrates indi-
cated. Data represent the mean of three experiments (n=3).
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4. Conclusions
The data we present point to the mouse AKR7A5 being the
functional orthologue of human AKR7A2 and rat AKR7A4.
This conclusion is based on the fact that it shares similar
enzyme kinetic properties, tissue distribution pattern and
does not appear to be inducible. In addition, we have shown
that it, like the human AKR7A2 and rat AKR7A4 enzymes,
is not the major SSA reductase in liver, but that it is likely to
contribute to 2-CBA reduction in that tissue. It may also play
a role in a£atoxin B1 dialdehyde reduction in mouse liver,
thus contributing to constitutive resistance to the a£atoxin.
A role for AKR7A5 as a SSA reductase in brain remains to
be established.
The characterisation of the enzyme described here will pave
the way for its function in vivo to be investigated through
the generation of a mouse line in which the AKR7A5 gene
has been knocked out. This will enable future investigations
into its role in detoxication and drug metabolism, as well
as its potential role in the metabolism of aldehydes in the
brain.
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